Pfizer (NYSE:PFE) Shares Up 0.6% – Time to Buy?

Pfizer Inc. (NYSE:PFE)’s share price traded up 0.6% on Wednesday . The company traded as high as $24.69 and last traded at $24.70. 8,969,546 shares traded hands during trading, a decline of 77% from the average session volume of 39,089,397 shares. The stock had previously closed at $24.54.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Bank of America reiterated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Trading Up 0.2 %

The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $139.40 billion, a PE ratio of 17.43, a P/E/G ratio of 0.64 and a beta of 0.61. The company’s 50-day moving average is $26.00 and its 200 day moving average is $26.84.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.10 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Pfizer

Several institutional investors have recently bought and sold shares of the stock. Retirement Wealth Solutions LLC acquired a new stake in Pfizer in the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer during the 4th quarter worth $26,000. Clarity Asset Management Inc. acquired a new position in Pfizer in the 4th quarter valued at $27,000. Gould Capital LLC raised its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 493 shares during the period. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the 4th quarter worth about $28,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.